Emergent BioSolutions Files 8-K for Financials

TL;DR

Emergent BioSolutions dropped an 8-K, mostly for financial docs. Check it out.

AI Summary

Emergent BioSolutions Inc. filed an 8-K on January 8, 2025, reporting an event on December 12, 2024. The filing is primarily for financial statements and exhibits, with no specific details on other events provided in the excerpt. The company is incorporated in Delaware and headquartered in Gaithersburg, Maryland.

Why It Matters

This filing indicates Emergent BioSolutions is providing updated financial information and exhibits to the SEC, which is standard practice but important for investors to review for company performance and disclosures.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for financial statements and exhibits, not indicating any immediate material adverse events.

Key Players & Entities

• Emergent BioSolutions Inc. (company) — Registrant
• December 12, 2024 (date) — Earliest event reported
• January 8, 2025 (date) — Filing date
• Gaithersburg, Maryland (location) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ange on which registered Common Stock, $0.001 par value per share EBS New York Stock
• $50 million — previously known as "AV7909") valued at $50 million. This modification relates to Emergent'
• $20 million — e (JPEO-CBRND), valued at approximately $20 million to supply Emergent's product BioThrax (

Filing Documents

• ebs-20241212.htm (8-K) — 32KB
• cyfendusmod.htm (EX-10.1) — 8KB
• biothraxmod.htm (EX-10.2) — 8KB
• pressrelease_121624.htm (EX-99.1) — 15KB
• pressrelease_010825.htm (EX-99.2) — 16KB
• biothraxmod001.jpg (GRAPHIC) — 248KB
• biothraxmod002.jpg (GRAPHIC) — 104KB
• biothraxmod003.jpg (GRAPHIC) — 90KB
• biothraxmod004.jpg (GRAPHIC) — 54KB
• cyfendusmod001.jpg (GRAPHIC) — 237KB
• cyfendusmod002.jpg (GRAPHIC) — 80KB
• cyfendusmod003.jpg (GRAPHIC) — 147KB
• cyfendusmod004.jpg (GRAPHIC) — 196KB
• cyfendusmod005.jpg (GRAPHIC) — 200KB
• cyfendusmod006.jpg (GRAPHIC) — 140KB
• cyfendusmod007.jpg (GRAPHIC) — 160KB
• cyfendusmod008.jpg (GRAPHIC) — 193KB
• cyfendusmod009.jpg (GRAPHIC) — 198KB
• cyfendusmod010.jpg (GRAPHIC) — 270KB
• cyfendusmod011.jpg (GRAPHIC) — 256KB
• cyfendusmod012.jpg (GRAPHIC) — 180KB
• cyfendusmod013.jpg (GRAPHIC) — 157KB
• cyfendusmod014.jpg (GRAPHIC) — 95KB
• image.jpg (GRAPHIC) — 7KB
• imagea.jpg (GRAPHIC) — 7KB
• 0001367644-25-000004.txt ( ) — 4380KB
• ebs-20241212.xsd (EX-101.SCH) — 2KB
• ebs-20241212_lab.xml (EX-101.LAB) — 22KB
• ebs-20241212_pre.xml (EX-101.PRE) — 13KB
• ebs-20241212_htm.xml (XML) — 3KB

01 Other Events

Item 8.01 Other Events. On December 16, 2024, Emergent BioSolutions Inc. ("Emergent") announced that it received a contract option modification ("Modification No. 18") of the BARDA AV7909 Contract (as defined below) from from the Office of the Assistant Secretary for Preparedness and Response to procure additional doses of CYFENDUS (Anthrax Vaccine Adsorbed, Adjuvanted) (previously known as "AV7909") valued at $50 million. This modification relates to Emergent's AV7909 development and procurement contract with the Biomedical Advanced Research and Development Authority, which became effective on September 30, 2016 (the "BARDA AV7909 Contract") and has been modified from time to time. The preceding description of Modification No. 18 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 18, filed as Exhibit 10.1 to this Current Report. The BARDA AV7909 Contract was filed as Exhibit 10.2 to Emergent's Quarterly Report on Form 10-Q for the period ended September 30, 2016, which was filed with the U.S. Securities and Exchange Commission on November 9, 2016. On January 8, 2025, the Company announced the exercise of a contract option and modification ("Modification No. 3") to the indefinite-delivery, indefinite-quantity (IDIQ) procurement contract (the "BioThrax IDIQ Contract") with the U.S. Department of Defense and led by The Joint Program Executive Office for Chemical, Biological Radiological and Nuclear Defense (JPEO-CBRND), valued at approximately $20 million to supply Emergent's product BioThrax (Anthrax Vaccine Adsorbed) for use by all branches of the U.S. military as Pre-Exposure Prophylaxis (PrEP) for anthrax disease. The preceding description of Modification No. 3 does not purport to be complete and is qualified in its entirety by reference to the full text of Modification No. 3, filed as Exhibit 10.2 to this Current Report. The BioThrax IDIQ Contract was filed as Exhibit 10.2 to the Company's Quar

01 Financial Statements and Exhibits

Item 9.01 Financial Statements and Exhibits. (d) Exhibits . Exhibit No. Description 10.1 Modification No. 18, effective December 12, 2024, to the BARDA AV7909 Contract. 10.2 Modification No. 3, effective December 13, 2024, to the BioThrax IDIQ Contract. 99.1 Press release issued by Emergent BioSolutions Inc. on December 16, 2024. 99.2 Press release issued by Emergent BioSolutions Inc. on January 8, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. EMERGENT BIOSOLUTIONS INC. Dated: January 8, 2025 By: /s/ Richard S. Lindahl Name: Richard S. Lindahl Title: Executive Vice President, Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR